CytomX Therapeutics, Inc.
CTMX
$4.00
$0.194.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.26% | 18.01% | 23.81% | 36.45% | 33.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.26% | 18.01% | 23.81% | 36.45% | 33.66% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -10.26% | 18.01% | 23.81% | 36.45% | 33.66% |
| SG&A Expenses | -11.99% | -3.77% | 5.39% | -0.97% | 6.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.62% | -13.94% | 3.00% | 5.02% | 16.85% |
| Operating Income | 246.44% | 653.67% | 232.15% | 485.49% | 185.09% |
| Income Before Tax | 87.67% | 219.88% | 104.35% | 865.75% | 304.68% |
| Income Tax Expenses | -80.08% | -93.79% | -94.01% | -94.27% | -56.43% |
| Earnings from Continuing Operations | 102.59% | 332.83% | 151.64% | 5,700.88% | 235.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.59% | 332.83% | 151.64% | 5,700.88% | 235.84% |
| EBIT | 246.44% | 653.67% | 232.15% | 485.49% | 185.09% |
| EBITDA | 186.81% | 486.76% | 192.43% | 721.10% | 253.00% |
| EPS Basic | 138.57% | 301.66% | 141.21% | 2,103.17% | 204.26% |
| Normalized Basic EPS | 120.28% | 197.87% | 95.16% | 1,209.34% | 1,451.76% |
| EPS Diluted | 143.38% | 316.39% | 146.64% | 1,633.06% | 198.97% |
| Normalized Diluted EPS | 121.82% | 199.83% | 96.10% | 1,212.15% | 1,426.74% |
| Average Basic Shares Outstanding | 39.99% | 17.57% | 10.29% | 14.46% | 19.29% |
| Average Diluted Shares Outstanding | 39.70% | 17.30% | 10.03% | 14.60% | 19.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |